· Phase II data in AML combining bemcentinib with low-dose chemotherapy and
NSCLC combining with KEYTRUDA
· Accepted for presentation at ASCO in June 2019
Bergen, Norway, 23 April 2019 - BerGenBio ASA (OSE: BGBIO) a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
multiple cancer indications, announces that the Company and its collaborators
will present new interim clinical and biomarker data from its extensive Phase II
clinical development programme with bemcentinib, a selective, oral AXL
inhibitor, at the 2019 annual meeting of the American Society of Clinical
Oncology (ASCO) at McCormick Place in Chicago, Illinois (31 May - 4 June 2019).
Abstract titles have been announced online at https://iplanner.asco.org/am2019/
and details of the presentations are below.
The posters presented at ASCO will be made available on www.bergenbio.com in the
Investors / Presentations section at time of presentation.
Sunday 2 June, 8:00 AM - 11:00 AM Central Daylight Time
A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL
inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and
preliminary stage II efficacy.
· Enriqueta Felip et al
· Session: Lung Cancer - Non-Small Cell Metastatic
· Location: Hall A, poster board #421, abstract 9098
Monday 3 June, 8:00 AM - 11:00 AM Central Daylight Time
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with
LDAC or decitabine exerts anti-leukaemic activity in AML pts unfit for intensive
chemotherapy: Phase II open-label study.
· Dr Sonja Loges et al
· Session: Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and
Allotransplant
· Location: Hall A, poster board #418, abstract 7043
-END-
About BerGenBio
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad Phase II oncology clinical development
programme focussed on combination and single agent therapy in lung cancer and
leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing
Phase I clinical testing. In parallel, BerGenBio is developing a companion
diagnostic test to identify those patient populations most likely to benefit
from bemcentinib: this is expected to facilitate more efficient registration
trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Jessica Hodgson, Chris Welsh, Nicholas Brown, Carina Jurs,
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.